SCHEMBL3520997

SCHEMBL3520997

COc1ccc(OC)c(CN2CCOC(C(=O)N(Cc3ccc4c(c3)OCCCO4)CC(C)C)C2)c1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.64
MCHR1 Q99705 2/20 0.44
KDM4E B2RXH2 5/20 0.41
MAPT P10636 1/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 4/20 0.40
TSHR P16473 2/20 0.40
GLA P06280 1/20 0.40
MEN1 O00255 2/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TACR1 P25103 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518617 0.93 PROKR2 (0.68) PROKR2MCHR1KDM4EKMT2AALDH1A1
SCHEMBL3516611 0.93 PROKR2 (0.59) PROKR2MCHR1KDM4EMAPTKMT2A
SCHEMBL3524424 0.92 PROKR2 (0.66) PROKR2MCHR1KDM4EKMT2AALDH1A1
SCHEMBL3517610 0.92 PROKR2 (0.66) PROKR2MCHR1KDM4EKMT2AALDH1A1
SCHEMBL3519888 0.92 PROKR2 (0.64) PROKR2MCHR1KDM4EMAPTALDH1A1
SCHEMBL3518632 0.91 PROKR2 (0.64) PROKR2MCHR1KDM4EALDH1A1LMNA
SCHEMBL3518689 0.91 PROKR2 (0.64) PROKR2MCHR1KDM4EALDH1A1LMNA
SCHEMBL3520587 0.90 PROKR2 (0.65) PROKR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL3516797 0.89 PROKR2 (0.62) PROKR2MCHR1KDM4EKMT2AALDH1A1
SCHEMBL3516884 0.89 PROKR2 (0.62) PROKR2MCHR1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885MCHR1 32/4885KDM4E 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.